❗❗ RESEARCH UPDATE ❗❗ A new manuscript has been accepted for publication in the Journal of Biomedical Materials Research: Part A. Full manuscript link coming soon... This paper characterizes a novel material, pz-PDMS™, that can: 💡 measure how heart cells beat in Humimic's organ models, helping us determine how the human body will respond to new treatments. 🧪 noninvasively quantify the contractile strength of cardiomyocytes, enabling real-time assessment of drug responses in vitro. This type of research forms the scientific foundation of Humimic’s CoCo Chip™ (a heart-on-chip platform), advancing our mission to replace outdated animal models with smarter, human-relevant platforms that accelerate drug discovery. We’re proud to see our work contributing to both academic knowledge and the future of biotech innovation. #OrganOnChip #Biotech #BiomedicalEngineering #Innovation #PeerReviewed #Research #Sensors #InVitroModels #Preclinical

Nanomedicine is about designing tiny materials — a thousand times smaller than a human hair — that can diagnose and treat diseases in smarter, safer, and more targeted ways. In our latest article, just published in Nanoscale (Nanoscience #RSCNano), we show how magnesium silicate nanotubes can be rapidly and precisely functionalized using a #microwave-assisted process. It means these nanotubes can be equipped with multiple functions — from carrying drugs, to enabling imaging, to supporting new therapies — all while being biocompatible. This is a step forward in building versatile nanomaterials for future precision medicine. 🔗 Read the full paper: https://lnkd.in/dX89tpDu #nanomedicine #nanotechnology #materials #research #precisionmedicine

🌍 MultiLab is powered by a multidisciplinary team of research institutes, med-tech startups, engineering labs, and healthcare providers. Together, we bring diagnostics from idea to implementation: 1. CyRIC | Cyprus Research & Innovation Center Ltd 2. bialoom 3. University of Ioannina 4. AMO GmbH 5. Multitel 6. Servizo Galego de Saúde 7. CNRS 8. Technische Universität Wien 9. Aquamonitrix® - On-line Analysers 10. DeepLab 11. Alpes Lasers Each brings domain expertise—from mid-IR chip design to regulatory approval and clinical workflows. #MultiLabProject #Consortium #EUResearch #Photonics #Microfluidics #Collaboration

Have you ever wondered how one tiny chip can test for multiple biomarkers at once? Sub-micron capture sites each with different capture chemistries enable successful microfluidic multiplexing. Check out how in our new blog article!

What’s the secret to successful multiplexing in microfluidics? Microfluidic technology has the potential to miniaturize and automate testing in genomics, proteomics, and at the point of care. What if we could detect dozens of biomarkers on one tiny chip? Advanced techniques in surface functionalization are now turning this vision into reality. Sub-micron capture sites can be created with unprecedented precision, each bearing different capture chemistries for multiplexed detection of analytes. Discover in the final article of our four-part series by Alexis Paul Tzannis how these breakthroughs are powering the next generation of biosensors, diagnostics, and organ-on-chip platforms, improving efficiency, specificity, and throughput. We also highlight real-world case studies from IMT and CSEM, and recent research showing how innovative combinations of chemistry and engineering are enabling scalable solutions. Want to deepen your knowledge? Read our latest blog article: https://lnkd.in/e5syUfZE Drop a comment if you’ve tried any of these approaches and share your experiences. #HSEAG #LabAutomation #LifeSciences #Diagnostics

1. Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy (Cryo-EM) machine, crucial for drug discovery. 2. The company aims for an initial public offering in 2027 after launching its first product this year. 3. Cryo-EM technology captures thousands of images to reconstruct 3D structures of biomolecules and was previously dominated by foreign firms. 4. Founded in 2017, Shuimu evolved from a partnership with Tsinghua University and Thermo Fisher, which stalled due to the US-China technology war. 5. The Totem Cryo-EM machine has received its first commercial order and features 50% domestically sourced hardware. 6. Shuimu aims to localize its supply chain and plans to ship over 1,000 units in six years. 7. The company integrates artificial intelligence with Cryo-EM technology to enhance data analysis efficiency. 8. Shuimu generated nearly 100 million yuan in revenue last year and aims for 250 million yuan this year, with plans to double revenue next year.

Microgravity isn’t just a new lab setting, it’s a new playbook. From higher-quality protein crystallization to scaffold-free 3D tissues, space-based bioprocessing is unlocking advantages impossible to replicate on Earth. This piece explores how microgravity can accelerate drug discovery, enable next-gen regenerative medicine, and power synthetic biology for in-space production — plus what it will take (automation, AI, commercial stations, new regs) to scale from ISS experiments to real manufacturing. Read the article: https://lnkd.in/edQJvjWv #BioPharma #Space #CDMO #BioTech #NiceInsight

The science behind MedTech innovation never ceases to amaze me—even now that I spend most of my time on the business side. The work below is a great example of how awe-inspiring fundamental research can be. This publication reveals that ⚡️electrical stimulation⚡️, delivered in a controlled manner, can accelerate wound healing 3-fold vs. non-stimulated controls. While these are in vitro results (i.e., in lab-grown cell models), it sounds like a promising avenue of research. If this translates clinically (a big if - I know...), it could become a game-changer for chronic wound care, particularly in diabetic patients. https://lnkd.in/e-nZvCXf Thank you Gloria Fabris, PhD for sharing this fascinating piece of research.

Molecular machine learning is becoming impossible to ignore. New Stanford / Arc collab for generative antibody design. ~4-22% experimental success across targets for de novo nanobody design, including nanomolar binding affinities. What a time to be alive! Preprint: https://lnkd.in/gXR6rMpR

This diagram captures a powerful truth: the future of innovation lies at the intersection of Nanotechnology, Biotechnology, Information Technology, and Cognitive Sciences collectively known as the NBIC System. Each field contributes foundational building blocks: Genes (Biotech), Atoms (Nano), Synapses (Cogno), and Bits (InfoTech) From DNA computing and neuromorphic engineering to smart environments and cyber-physical infrastructures, NBIC is driving breakthroughs that touch everything from personalized medicine to intelligent design. As someone deeply engaged in nanobiotechnology, I see NBIC not as a concept, but as a strategic framework for solving complex challenges and building a more integrated, intelligent future. Let’s keep pushing boundaries. #NBIC #Innovation #Biotech #Nanotech #CognitiveScience #InformationTechnology #FutureOfScience #NanoBioTechnology